Rich Smith, The Motley Fool Thu, November 12, 2026 at 12:33 PM EST 3 min read MRNA -1.73% NVDA -4.59% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
MRNA pioneer Moderna (NASDAQ:MRNA) stock tumbled more than 6% in early trading Thursday before clawing its way back to a 2% loss as of 11:50 a.m. ET. The reason:
Moderna just held an "analyst day" in which it laid out financial projections through the end of this year... but didn't tell investors much about next year.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Moderna forecast full-year 2026 revenue growth between 15% and 25%, significantly ahead of prior predictions for 10% growth. Profit margins are also firming up, with management saying it might grow gross margin by 10%. Simultaneously, Moderna is cutting costs to hold onto more of those profits at the operating and net profit levels.
Assuming all goes as planned, this implies 2026 revenue will come in around $2.3 billion, and that losses -- $7.26 per share in 2025 -- might shrink.
That's both bad and good news. According to data from Yahoo! Finance, Wall Street expects Moderna to post $2.4 billion in 2026 sales. (So $2.3 billion would be a sales "miss.) Conversely, the Street estimates Moderna will lose $7.37 per share this year. If margins rise as Moderna hopes, Moderna might beat that estimate.
Which would be great news for 2026 -- but what about 2027? Here's where investors may be more concerned. Moderna says it has "accelerated cost reductions, bringing forward the previously announced 2027 cash cost framework into 2026." But Moderna's looking at "approximately $4 billion in cash costs in 2027" -- about the same level of cash burn Moderna experienced in 2023 and 2024, but up from the $2.1 billion Moderna burned in 2025. Worse, management says annual cash costs will average between $4 billion and $4.5 billion from 2027 through 2030 -- so costs are going up in the medium term.
That's not the result you want to see in the middle of a cost-cutting campaign. It may be the reason Moderna stock is sinking today.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $348,060!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,067,492!*
Now, it's worth noting Stock Advisor's total average return is 849% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of November 12, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Moderna. The Motley Fool has a disclosure policy.
Why Moderna Stock Dropped on Thursday was originally published by The Motley Fool
